Expand ACRV Menu
ACRV MENU

ACRV Latest Press Releases

-- May 21, 2026 --

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit Globe Newswire 7:30 AM

-- May 15, 2026 --

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- May 13, 2026 --

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts Globe Newswire 4:10 PM

-- April 17, 2026 --

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities Globe Newswire 4:00 PM

-- April 15, 2026 --

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- March 19, 2026 --

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Globe Newswire 7:21 AM

-- March 17, 2026 --

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors Globe Newswire 5:54 PM

-- February 24, 2026 --

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Globe Newswire 8:00 AM

-- February 23, 2026 --

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress Globe Newswire 8:00 AM

-- February 18, 2026 --

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory Globe Newswire 8:00 AM

-- February 17, 2026 --

Registration Momentum Builds Across the Oncology Pipeline Globe Newswire 10:48 AM

-- January 23, 2026 --

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress Globe Newswire 8:11 AM

-- January 8, 2026 --

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 Globe Newswire 7:30 AM

-- January 6, 2026 --

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes